ADMA BIOLOGICS, INC. Operating Lease Right-of-Use Assets
ADMA BIOLOGICS, INC. (ADMA) had Operating Lease Right-of-Use Assets of $6.15 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $6.15M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $6.40M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $6.65M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $9.27M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $6.15M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $6.40M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $6.65M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $9.27M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $8.96M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $8.02M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $8.63M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $8.90M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $9.15M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $9.40M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $9.63M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $9.75M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $10.00M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $10.25M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $10.48M 10-K · filed 2024-02-28 | $10.49M 10-K · filed 2023-03-23 |
| 2022-09-30 | $10.34M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $10.55M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $7.11M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $7.26M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $6.69M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $6.83M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $6.20M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $4.26M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $2.78M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.70M 10-Q · filed 2020-08-05 | |
| 2019-12-31 | $1.25M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |